This article is more than 5 years old. Information may no longer be current.

VIDEO: SGLT inhibitors for type 1 diabetes require more study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LOS ANGELES — In this video exclusive, Mohammad El-rifai, MD, an endocrinologist at Cheyenne Regional Medical Center, describes the benefits and risks of using SGLT inhibitors in type 1 diabetes.

Although these agents have received interest as possible adjunctive therapies to insulin for type 1 diabetes, SGLT2 inhibitors and a dual SGLT1/SGLT2 inhibitor have not been approved for use in this population, primarily because of concerns about diabetic ketoacidosis.

Watch the video for more.